GEXVal Receives Funding from a Parkinson’s Research Program at The Michael J. Fox Foundation

株式会社GEXVal
2025年2月14日

GEXVal Inc. (President & CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, "GEXVal") is pleased to announce that it has been selected to receive research funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) ⁽¹⁾ for research into non-motor symptoms of Parkinson's disease (PD)⁽²⁾ .

The news release from MJFF can be viewed here:
URL: https://www.michaeljfox.org/grant/investigation-novel-therapeutic-approach-non-motor-symptoms-parkinsons-disease

The research grant of approximately USD 1.3 million (approximately JPY 200 million) comes from MJFF's Parkinson's Disease Therapeutics Pipeline Program. The program will support preclinical research using multiple Parkinson's disease animal models.

Dr. Kohei Shimada, our Chief Scientific Officer, stated, "Non-motor symptoms of Parkinson’s disease represent a significant unmet medical needs. We are grateful for this opportunity to advance our research program through MJFF's support."

GEXVal strives to ensure Treatment Reaches the Unreached, focusing on rare diseases and underserved medical conditions. By leveraging its proprietary AI-driven pharmacoinformatics technology (RePhaIND^®(3)), the company illuminates paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver innovative, life-changing medicines that bring new hope to patients and their families.

Notes:
1）About MJFF:
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is the world’s largest nonprofit funder of Parkinson’s research. For information about the foundation and its program, please visit: https://www.michaeljfox.org/what-we-fund

2）About Parkinson’s disease:
Parkinson's disease is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, muscle rigidity, tremors, and postural instability, as well as non-motor symptoms including sleep disorders, autonomic dysfunction, depression, anxiety, and cognitive impairment, which can significantly impact daily activities.
In Japan, Parkinson's disease is designated as an intractable disease by the Ministry of Health, Labour and Welfare (MHLW), making patients eligible for medical expense support and assistance programs.

For more information:
-MJFF Parkinson’s Disease Information: https://www.michaeljfox.org/parkinsons-101
-MHLW designated intractable diseases website [Japanese only] : https://www.mhlw.go.jp/stf/newpage_36011.html?utm_source=chatgpt.com

3）RePhaIND® is a registered trademark of GEXVal Inc.

有关本事宜请咨询:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com